Study on PLGA-based nanoparticles in gynecological diseases
10.12092/j.issn.1009-2501.2023.04.013
- Author:
Yetao CHEN
1
;
Mengyao WU
1
;
Fangzhu WAN
1
;
Haibo HE
1
;
Junyu HE
2
;
Hongbo TANG
3
Author Information
1. Hubei Key Laboratory of Natural Products Research and Development, Yichang Key Laboratory of Development and Utilization of Health Products with Drug and Food Homology, China Three Gorges University
2. Basic Medical College of China Three Gorges University
3. Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University
- Publication Type:Journal Article
- Keywords:
gynecological diseases;
nanoparticles;
polylactic-co-glycolic acid
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(4):455-462
- CountryChina
- Language:Chinese
-
Abstract:
Polylactic-co-glycolic acid (PLGA) has the characteristics of biocompatibility, biodegradability, modifiability, and slow release, which has attracted extensive attention in the treatment of gynecological diseases. This paper summarizes the relevant literature reports at home and abroad in recent years, expounds the research situation of PLGA nanoparticles as drug carriers in gynecological diseases such as ovarian cancer, breast cancer, cervical cancer and endometriosis, and looks forward to its great potential in clinical application in gynecological diseases, providing guidance for its prevention and treatment in gynecological diseases.
